SECOND-LINE DOCETAXEL MONOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AT NGHE AN ONCOLOGY HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the treatment outcomes of second-line Docetaxel monotherapy in patients with esophageal squamous cell carcinoma at Nghe An Oncology Hospital.
Subjects and methods: A retrospective descriptive study was conducted on 61 patients with esophageal squamous cell carcinoma who received second-line Docetaxel monotherapy between January 2023 and December 2025 at Nghe An Oncology Hospital.
Results: The mean age of the patients was 59.79 ± 6.7 years. The proportion of patients completing six cycles of chemotherapy was 45.9%. The disease control rate was 49.2%, with a partial response rate of 32.8%. Tumor T stage, overall disease stage, number of metastatic organs, and sites of metastasis were significantly associated with treatment response (p < 0.05). The most common hematologic toxicity was neutropenia, with grade 3-4 neutropenia occurring in 14.8% of patients; febrile neutropenia was observed in 8.2% of patients. Other adverse events were predominantly grade 1-2.
Conclusion: Second-line Docetaxel monotherapy demonstrated favorable efficacy and an acceptable safety profile in patients with esophageal squamous cell carcinoma who experienced disease progression following first-line treatment.
Article Details
Keywords
Docetaxel, esophageal squamous cell carcinoma, second-line therapy.
References
[2] Song Z et al. Second-line Docetaxel-based chemotherapy after failure of Fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther, 2014: 7: 1875-81. doi: 10.2147/OTT.S66525.
[3] Albertsson M et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol, 2007, 24 (4): 407-12. doi: 10.1007/s12032-007-0028-6.
[4] Ford H.E.R, Marshall A et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol, 2014, 15 (1): 78-86. doi: 10.1016/S1470-2045(13)70549-7.
[5] Muro K, Hamaguchi T et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol, 2004, 15 (6): 955-9. doi: 10.1093/annonc/mdh231.
[6] Nguyễn Việt Anh, Cao Thị Thanh, Phạm Văn Thắng. Kết quả điều trị phác đồ Docetaxel-Cisplatin trong ung thư biểu mô thực quản giai đoạn tái phát, di căn. Tạp chí Y học Việt Nam, 2025, 553 (3): 69-73. doi: 10.51298/vmj.v553i3.15439
[7] Ghazy H.F, El-Hadaad H.A et al. Metastatic esophageal carcinoma: prognostic factors and survival. J Gastrointest Cancer. 2022 Jun; 53 (2): 446-50. doi: 10.1007/s12029-021-00610-4.
[8] Trần Thị Kim Anh, Trịnh Lê Huy. Kết quả điều trị phác đồ M-DCF trong ung thư biểu mô thực quản giai đoạn di căn tại Bệnh viện Đại học Y Hà Nội. Tạp chí Y học Việt Nam, 2022, 519 (1): 115-120. doi: 10.51298/vmj.v519i1.3529
[9] Nguyễn Thu Trang, Đỗ Anh Tú. Kết quả hóa trị phác đồ Paclitaxel và Carboplatin bước 1 trên người bệnh ung thư thực quản giai đoạn IV tại Bệnh viện K. Tạp chí Y học Việt Nam, 2024, 536 (2): 39-42. doi: 10.51298/vmj.v536i2.8871